A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4545 (2006.01) A61K 9/00 (2006.01) A61K 31/423 (2006.01) A61K 47/40 (2006.01) A61P 7/02 (2006.01)
Patent
CA 2619214
An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted .beta.-cyclodextrin, preferably, sulfobutyl ether .beta.- cyclodextrin (SBE-CD) or hydroxypropyl-.beta.-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome employing the above formulation is also provided.
La présente invention se rapporte à une formulation d'inhibiteur de Facteur Xa injectable qui renferme l'inhibiteur de Facteur Xa razaxaban ou apixaban, un agent de solubilisation qui est une .beta.-cyclodextrine substituée, de préférence, une sulfobutyle éther .beta.-cyclodextrine (SBE-CD) ou une hydroxypropyle-.beta.-cyclodextrine (HPB-CD), et de l'eau. La présente invention concerne également une méthode permettant de prévenir ou de traiter la thrombose veineuse, la thrombose veineuse profonde et le syndrome coronarien aigu au moyen de la formulation ci-dessus.
Gogate Uday Shankar
Malloy Timothy M.
Nassar Munir N.
Bristol-Myers Squibb Company
Gowling Lafleur Henderson Llp
LandOfFree
Factor xa inhibitor inclusion complex with cyclodextrin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor xa inhibitor inclusion complex with cyclodextrin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor xa inhibitor inclusion complex with cyclodextrin will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1350997